تفاصيل الوثيقة نوع الوثيقة : مقال في مجلة دورية  عنوان الوثيقة : استخدام علاج البريقابالين لعلاج صرع الأطفال المستعصى Pregabalin: preliminary experience in intractable childhood epilepsy.   لغة الوثيقة : الانجليزية  المستخلص : Pregabalin is a new antiepileptic drug that acts at presynaptic calcium channels, modulating neurotransmitter release. We report our experience in treating consecutive children with severe drug resistant epilepsy in a prospective, open label, add on trial. Nineteen children (63% males) aged 4-15 years (mean 9.7, SD 2.9) were included. Most children (74%) had daily seizures that failed multiple drugs (mean 5). The epilepsy was symptomatic in 58%, and 74% had associated cognitive deficits. The seizures were mixed in 9 (47%) and 4 (21%) had Lennox Gastaut syndrome. Pregabalin was maintained at 150-300 mg/day. On pregabalin, 1 (6%) child became seizure free and 7 (37%) had >50% seizure reduction. The percentage of children with daily seizure was reduced from 74% before pregabalin to 37% afterward (p <0.002). Side effects were noted in 6 (32%) with somnolence, weight gain, dizziness, or behavioral change. The drug had to be withdrawn in 5 (26%) children for of lack of efficacy and in 2 (11%) for worsening of myoclonic epilepsy. We conclude that pregabalin is a useful addition in the treatment of refractory childhood epilepsy. The drug should be used with caution in myoclonic epilepsy. Controlled studies are needed to establish long term efficacy and tolerability.  ردمد : 0930-2794  اسم الدورية : Pediatric Neurology  المجلد : 5  العدد : 40  سنة النشر : 2009 هـ 2009 م  نوع المقالة : مقالة علمية  تاريخ الاضافة على الموقع : Wednesday, March 10, 2010  الباحثون اسم الباحث (عربي) اسم الباحث (انجليزي) نوع الباحث المرتبة العلمية البريد الالكتروني محمد جان jan, Mohammed باحث دكتوراه   الملفات اسم الملف النوع الوصف  25886.doc doc   الرجوع إلى صفحة الأبحاث